TG THERAPEUTICS, INC. (TGTX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 268.49M USD | Liabilities, Current |
| Cash and equivalents | 482.57M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 401.56M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 147.97M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $268.49M | $482.57M | (m) | $401.56M | $147.97M | (m) |
| 2026-03-31 | (m) | $187.11M | $442.21M | (m) | $392.05M | $129.03M | (m) |
| 2025-12-31 | (m) | $153.76M | $79.15M | (m) | $305.63M | $125.59M | (m) |
| 2025-09-30 | (m) | $156.81M | $74.08M | (m) | $265.38M | $146.95M | (m) |
| 2025-06-30 | (m) | $171.89M | $129.13M | (m) | $231.52M | $155.20M | (m) |
| 2025-03-31 | (m) | $160.21M | $132.14M | (m) | $190.12M | $157.76M | (m) |
| 2024-12-31 | (m) | $90.68M | $179.89M | (m) | $129.19M | $110.46M | (m) |
| 2024-09-30 | (m) | $125.11M | $195.82M | (m) | $115.73M | $84.67M | (m) |
| 2024-06-30 | (m) | $108.66M | $82.91M | (m) | $83.61M | $81.24M | (m) |
| 2024-03-31 | (m) | $99.68M | $75.48M | (m) | $64.98M | $77.72M | (m) |
| 2023-12-31 | (m) | $53.72M | $92.93M | (m) | $51.09M | $39.82M | (m) |
| 2023-09-30 | (m) | $57.68M | $150.90M | (m) | (m) | $33.55M | (m) |
| 2023-06-30 | (m) | $72.67M | $97.01M | (m) | (m) | $30.23M | (m) |
| 2023-03-31 | (m) | $63.08M | $61.47M | (m) | (m) | $27.22M | (m) |
| 2022-12-31 | (m) | $53.20M | $102.30M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $36.45M | $109.86M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $43.33M | $147.07M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $54.66M | $185.68M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $65.38M | $298.89M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $87.66M | $326.51M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $87.55M | $401.71M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $92.49M | $471.51M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $87.55M | $553.44M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $77.67M | $254.15M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $67.54M | $260.51M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $63.12M | $52.05M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $84.45M | $112.64M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $80.20M | $44.67M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $55.97M | $57.23M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $60.94M | $64.35M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $38.85M | $41.96M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $40.24M | $70.72M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $36.94M | $105.67M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $33.34M | $82.90M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $27.96M | $56.72M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $19.79M | $91.84M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $20.76M | $77.60M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $19.73M | $95.64M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $16.88M | $25.03M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $16.88M | $29.16M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $14.12M | $28.58M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $8.89M | $36.48M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $10.53M | $55.06M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $9.69M | $65.46M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $9.21M | $60.30M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $9.55M | $86.00M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $5.12M | $55.71M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $8.90M | $53.23M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $2.61M | $37.08M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $1.99M | $49.60M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $6.32M | $40.49M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $5.68M | $50.18M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $3.47M | $13.42M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $2.47M | $15.19M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $2.22M | $16.46M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $2.96M | $17.37M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $2.35M | $20.37M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $1.22M | $20.92M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $1.61M | $9.75M | (m) | (m) | (m) | (m) |
| 2011-11-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $1.52M | $212.28K | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $3.78M | $492.51K | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $3.29M | $478.67K | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $1.08M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $1.57M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $18.00K | (m) | (m) | (m) | (m) |
| 2001-08-05 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |